3 Biopharmas on Buyout Watch
The pharmaceutical merger and acquisition (M&A) scene is heating up. Speaking to this point, Pfizer recently doled out $5.4 billion to acquire Global Blood Therapeutics for its sickle cell disease assets. Amgen spent $3.7 billion on a deal earlier this month for ChemoCentryx in order to attain the newly approved ANCA-associated vasculitis drug Tavneos. And Merck is rumored to be in advanced talks to buy the cancer specialist Seagen.
Four key factors are driving this notable uptick in pharma M&A.
With this background in mind, here is a brief look at three biotech companies that could be acquired soon.
Source Fool.com
